Stocktoria
Mirum Pharmaceuticals, Inc. MIRM
Mirum Pharmaceuticals, Inc. (MIRM) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $521.3M at a -4.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-15 | Citizens | Market Outperform (main) |
| 2026-06-11 | Morgan Stanley | Overweight (main) |
| 2026-06-02 | Citigroup | Buy (init) |
| 2026-05-19 | Wolfe Research | Outperform (init) |
| 2026-05-07 | TD Cowen | Buy (main) |
| 2026-05-07 | RBC Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.408 |
| Retained earnings / assets | -0.792 |
| EBIT / assets | -0.026 |
| Equity / liabilities | 0.596 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | 4/9 | 0.54 | — | +54.7% |
| BBIO | BridgeBio Pharma, Inc. | 1/9 | -14.22 | — | +126.3% |
| HCM | HUTCHMED (China) Ltd | 4/9 | 6.45 | 31.3 | -13% |
| TVTX | Travere Therapeutics, Inc. | 5/9 | -5.38 | — | +110.5% |
| NATR | NATURES SUNSHINE PRODUCTS INC | 6/9 | 5.82 | 18.9 | +5.7% |
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
| ZLAB | Zai Lab Ltd | 3/9 | -3.61 | — | +15.3% |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
FAQ
Is MIRM financially healthy?
Mirum Pharmaceuticals, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MIRM pay a dividend?
No, Mirum Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is MIRM?
In FY2025, Mirum Pharmaceuticals, Inc. had a net margin of -4.5% and a return on equity of -7.4%.
What is the analyst price target for MIRM?
The average Wall-Street price target for Mirum Pharmaceuticals, Inc. is $145.36, about 46.9% above the recent price, from 14 analysts (consensus: strong buy).
Is MIRM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Mirum Pharmaceuticals, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.